1 |
F. Theibaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan and M.C Willingham, Localization of the multidrug resistance gene product P-glycoprotein in normal human tissues, Proc. Natl. Acad. Sci., 84, 7735-7738 (1987)
DOI
|
2 |
B.L. Lum and M.P. Gosland, MDR expression in normal tissues. Pharmacologic implications for the clinical use of Pglycoprotein inhibitors. Hematol. Oncol. Clin. North Am., 9, 319-336 (1995)
|
3 |
M.F. Fromm, P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drug, Int. J. Clin. Pharmacol. Ther., 38, 69-74 (2000)
DOI
|
4 |
R.W. Stenkampf and W.D. Klohs, Possible link between the intrinsic drug resistance of colon tumor and a detoxification mechanism of intestinal cell, Cancer Res., 48, 3025-3030 (1988)
|
5 |
J.D. Potter, Cancer prevention: epidemiology and experiment, Cancer Lett., 114, 7-9 (1997)
DOI
ScienceOn
|
6 |
M.J. Wargovich, Experimental evidence for cancer preventive elements in foods, Cancer Lett., 114, 11-17 (1997)
DOI
ScienceOn
|
7 |
E. Chieli, N. Romiti, F. Cervelli and R. Tongiani, Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes, Life Sci., 57, 1741-1751 (1995)
DOI
ScienceOn
|
8 |
J.W. Critchfield, C.J. Welsh, J.M. Phang and G.C. Yeh, Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells: activation of P-glycoprotein as a putative mechanisms, Biochem. Pharmacol., 48, 1437-1445 (1994)
DOI
ScienceOn
|
9 |
G.C Yeh, J. Lopaczynska, C.M. Poore and J.M. Phang, A new functional role for P-glycoprotein: Efflux pump for benzo [ ]pyrene in human breast cancer MCF-7 cells, Cancer Res., 52, 6692-6695 (1992)
|
10 |
P. Talalay and Y. Zhang, Chemoprotection against cancer by isothiocyanates and glucosinolates. Biochem. Soc. Trans., 24, 806-810 (1996)
DOI
|
11 |
Y. Zhang and P. Talalay, Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms, Cancer Res. (suppl), 54, 1976-1981 (1994)
|
12 |
P.F. Juranka, R.L. Zastawny and V. Ling, P-glycoprotein multidrug resistance and a superfamily of membrane associated transport proteins, FASEB J., 3, 2583-2592 (1989)
|
13 |
S.A.W. Fuqua, I.M. Moretti-Rojas, S.L. Schneider and W.L. McGuire, P-glycoprotein expression in human breast cancer cells, Cancer Res., 47, 2103-2106 (1987)
|
14 |
A. Somogyi, Renal transport of drugs: specificity and mechanisms, Clin. Exp. Pharmacol. Physiol., 23, 986-989 (1996)
DOI
ScienceOn
|
15 |
J.A. Endicott and V. Ling, The biochemistry of P-glycoprotein-mediated multidrug resistance, Ann. Rev. Biochem., 58, 137-171 (1989).
DOI
ScienceOn
|
16 |
M.M. Gottesman and I. Pasran, Biochemistry of multidrug resistance mediated by the multidrug transporter, Ann. Rev. Biochem, 62, 385-427 (1993)
DOI
ScienceOn
|
17 |
V.J. Wacher, L. Salphati and L.Z. Benet, Active secretion and enterocyte drug metabolism barriers to drug absorption. Adv. Drug Del. Rev., 20, 99-112 (1996)
DOI
ScienceOn
|
18 |
G. Koren, Clinical pharmacokinetic significance of the renal tubular secretion of digoxin. Clin. Pharmacol. Ther., 44, 467-477 (1988)
DOI
ScienceOn
|
19 |
J.M. Phang, C.M. Poore, J. Lopaczynska and G.C Yeh, Flavol-stimulated efflux of 7, 12-dimethylbenz( )anthracene in multidrug-resistant breast cancer cells. Cancer Res., 53, 5977-5981 (1993)
|
20 |
T. Ikegawa, H. Ohtani, N. Koyabu, M. Juichi, Y. Iwase, C Ito, H. Furukawa, M. Naito, T. Tsuruo and Y. Sawada, Inhibition of P-glycoprotein by flavonoid derivatives in adriamycinresistant human myelogenous leukemia (K562/ADM) cell, Cancer Lett., 177, 89-93 (2002)
DOI
ScienceOn
|
21 |
P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenny and M.R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer. Inst., 82, 1107-1112 (1990)
DOI
|
22 |
G. Scambia, F.O. Ranelleti, P.B. Panici, R. DiVincenzo, G. Bonanno, G. Ferrandina, M. Piantelli, S. Bussa, C Rumi, M. Cianfriglia and S. Mancuso, Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target, Cancer Chemother. Pharmacol., 34, 459-464 (1994)
DOI
|
23 |
W.G. Harker, F.R. Mackintosh and B.I. Sikic, Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drug, Cancer Res., 43, 4943-4950 (1983)
|
24 |
G. Harker and B.I. Sikic, Multidrug (Pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA, Cancer Res., 45, 4091-4096 (1985)
|
25 |
E.J. Go, S.Y. Chung, N.H. Kim and H.J. Lee, Modulation of P-glycoprotein activity by flavonoids in human uterine sarcoma cells, J. Kor. Pharm. Sci., 33, 305-310 (2003)
|
26 |
L. Movileanu, I. Neagoe and M.L. Flonta, Interation of the antioxidant flavonoid quercetin with planar lipid bilayers, Int. J. Pharm., 205, 135-146 (2000)
DOI
ScienceOn
|